Last reviewed 2026-04-23 · How we verify

HR17031 injection

HR17031 is an anti-angiogenic agent that inhibits vascular endothelial growth factor (VEGF) signaling to suppress tumor blood vessel formation.

HR17031 is an anti-angiogenic agent that inhibits vascular endothelial growth factor (VEGF) signaling to suppress tumor blood vessel formation. Used for Solid tumors (specific indications under investigation in phase 3).

At a glance

Mechanism of action

HR17031 functions as a VEGF pathway inhibitor, blocking the formation of new blood vessels that tumors depend on for growth and metastasis. By targeting VEGF receptors, the drug starves tumors of their blood supply, thereby inhibiting tumor progression. This anti-angiogenic mechanism is commonly employed in oncology to reduce tumor vascularization and improve therapeutic outcomes.

Approved indications

• Solid tumors (specific indications under investigation in phase 3)

Common side effects

• Hypertension
• Proteinuria
• Fatigue
• Diarrhea

Key clinical trials

• A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes (PHASE3)
• A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes (PHASE3)
• A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites (PHASE1)
• A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes (PHASE2)
• Pharmacokinetics of HR17031 Injection in Healthy Subjects (PHASE1)
• A Trial of HR17031 Injection With Renal Insufficiency (PHASE1)
• A Trial of HR17031 Injection With Hepatic Insufficiency (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.